Grifols phase 3 Covid-19 trial of hyperimmune globulins fails to meet objective
Spanish pharma company Grifols said that the phase 3 ITAC clinical trial assessing hyperimmune globulins as a treatment for patients hospitalized with Covid-19 has failed to meet its primary endpoints. ITAC expands to Inpatient Treatment with Anti-Coronavirus Immunoglobulin. Also called INSIGHT-013, the late-stage trial was sponsored and supported by the US National Institute of Allergy […]